Principal Financial Group Inc Adc Therapeutics Sa Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$2.87 - $5.24 $287 - $524	-100 Reduced 0.02%	400,300 $1.54 Million
Q3 2022 Nov 09, 2022	SELL	$4.66 - $10.31 $26,571 - $58,787	-5,702 Reduced 1.4%	400,400 $1.93 Million
Q2 2022 Aug 10, 2022	BUY	$5.96 - $14.99 $601,101 - $1.51 Million	100,856 Added 33.04%	406,102 $3.23 Million
Q1 2022 May 09, 2022	BUY	$13.28 - $20.03 $26,719 - $40,300	2,012 Added 0.66%	305,246 $4.48 Million
Q4 2021 Feb 09, 2022	BUY	$19.29 - $31.51 $220,465 - $360,127	11,429 Added 3.92%	303,234 $6.13 Million
Q3 2021 Nov 09, 2021	SELL	$20.45 - $30.0 $68,671 - $100,740	-3,358 Reduced 1.14%	291,805 $7.93 Million
Q2 2021 Aug 10, 2021	BUY	$20.38 - $27.04 $1.54 Million - $2.05 Million	75,664 Added 34.47%	295,163 $7.19 Million
Q1 2021 May 10, 2021	BUY	$22.75 - $34.05 $148,443 - $222,176	6,525 Added 3.06%	219,499 $5.36 Million
Q4 2020 Feb 08, 2021	SELL	$25.26 - $38.02 $35,515 - $53,456	-1,406 Reduced 0.66%	212,974 $6.82 Million
Q3 2020 Nov 06, 2020	BUY	$32.87 - $51.05 $2.01 Million - $3.13 Million	61,293 Added 40.04%	214,380 $7.07 Million
Q2 2020 Sep 04, 2020	BUY	$29.65 - $46.81 $4.54 Million - $7.17 Million	153,087 New	153,087 $7.17 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $135M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.